Skip to main content

Advertisement

SpringerLink
Log in

Risks of Infection among the Older Inflammatory Bowel Disease Patients

  • Geriatrics (S Katz, Section Editor)
  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Accumulating evidence has demonstrated improved clinical outcomes with earlier initiation of immunosuppressive therapy for patients with inflammatory bowel disease (IBD). However, current evidence-based treatment paradigms are not often applied to the older IBD patients, as they represent a higher-risk group for disease and medication-associated complications, particularly infection. Serious infections, associated with increased hospitalizations, morbidity, and mortality, are more common among the older IBD patients. Although immunosuppression and advanced age are risk factors for infection, additional variables such as increasing disease activity, comorbidity, and declining functional status also play a role. Finding the optimal balance between therapeutic efficacy and safety for older IBD patients with moderate to severe disease activity poses a great challenge to the practicing clinician particularly as the therapeutic armamentarium expands to include more immunologic targets in the future to be used in combination with currently available therapies. Patient selection, looking beyond numeric age, with prompt and appropriate medication prescribing relative to disease activity and corticosteroid dependence is key to maximizing efficacy and decreasing infection-related risks. Additionally, practitioners should be proactive with respect to older IBD patients with an emphasis on preventative care, including vaccinations and nutritional and functional status assessments, to address potentially modifiable risk factors for serious infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54.

    Article  PubMed  Google Scholar 

  2. Nguyen GC, Tuskey A, Dassopoulos T, et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007;13:1529–35.

    Article  PubMed  Google Scholar 

  3. Ananthakrishnan AN, McGinley EL, Saeian K, et al. Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994–2005. Am J Gastroenterol. 2010;105:363–70.

    Article  PubMed  Google Scholar 

  4. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17:1603–9.

    Article  CAS  PubMed  Google Scholar 

  5. 2010 Census Data on Aging. Available at http://www.aoa.gov/aoaroot/aging_statistics/Census_Population/census2010/Index.aspx. Last modified December 5, 2011.

  6. Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis. 2009;15:182–9.

    Article  PubMed  Google Scholar 

  7. Ananthakrishnan AN, McGinley EL. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. J Crohn’s Colitis. 2012;7(2):107–12.

    Article  Google Scholar 

  8. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with crohn’s disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107:1409–22. Prospective observational study of risk factors for serious infection among IBD patients noting that although increasing age is associated with increased risk of infection, moderate to severe disease activity and steroid use have greater risk.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Rowe TA, Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. Infect Dis Clin N Am. 2014;28:75–89.

    Article  Google Scholar 

  10. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:345–51.

    Article  PubMed  Google Scholar 

  11. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57:205–10.

    Article  CAS  PubMed  Google Scholar 

  12. Britton E, McLaughlin JT. Ageing and the gut. Proc Nutr Soc. 2013;72:173–7.

    Article  PubMed  Google Scholar 

  13. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5:133–9.

    Article  CAS  PubMed  Google Scholar 

  14. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA J Am Med Assoc. 2011;306:2331–9.

    Article  CAS  Google Scholar 

  15. Maziere S, Couturier P, Gavazzi G. Impact of functional status on the onset of nosocomial infections in an acute care for elders unit. J Nutr Health Aging. 2013;17:903–7.

    Article  CAS  PubMed  Google Scholar 

  16. Grau I, Ardanuy C, Calatayud L, et al. Smoking and alcohol abuse are the most preventable risk factors for invasive pneumonia and other pneumococcal infections. Int J Infect Dis 2014.

  17. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Ha C, Bayless T, Wick E. Increased incidence of post-operative complications in older inflammatory bowel disease patients having intestinal surgery. Gastroenterology. 2012;142:S25.

    Google Scholar 

  19. Ha C, Bayless T, Wick E. In-hospital morbidity among older inflammatory bowel disease patients having intestinal surgery is predicted by the simplified comorbidity score and functional status. Gastroenterology. 2013;144:S189.

    Google Scholar 

  20. Ha CY, Newberry RD, Stone CD, et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol. 2010;8(8):682–7.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Charpentier C, Salleron J, Savoye G, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2013. doi:10.1136/gutjnl-2012-303864.

    PubMed  Google Scholar 

  22. Juneja M, Baidoo L, Schwartz MB, et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci. 2012;57:2408–15.

    Article  PubMed  Google Scholar 

  23. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501–23.

    Article  PubMed  Google Scholar 

  24. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459–63.

    Article  PubMed  Google Scholar 

  25. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–22.

    Article  PubMed  Google Scholar 

  26. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–8. quiz e10-1.

    Article  PubMed  Google Scholar 

  27. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. Inflamm Bowel Dis. 2009;15:1295–301.

    Article  PubMed  Google Scholar 

  28. Ardizzone S, Cassinotti A, Duca P, et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9:483–9. e3.

    Article  PubMed  Google Scholar 

  29. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141:1194–201.

    Article  CAS  PubMed  Google Scholar 

  30. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis. 2012;18:1006–10.

    Article  PubMed  Google Scholar 

  31. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–95.

    Article  CAS  PubMed  Google Scholar 

  32. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146:392–400. e3.

    Article  CAS  PubMed  Google Scholar 

  33. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn’s disease. Gastroenterology. 2014;146:681–8. e1.

    Article  CAS  PubMed  Google Scholar 

  34. Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohn’s Colitis. 2012;7(11):878–89.

    Article  Google Scholar 

  35. Feagins LA, Spechler SJ. Biologic agent use varies inversely with age at diagnosis in Crohn’s disease. Dig Dis Sci. 2010;55:3164–70.

    Article  PubMed  Google Scholar 

  36. Ortega TL, Vermeire S, Ballet V, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Gastroenterology. 2014;146:S579.

    Article  Google Scholar 

  37. Bhushan A, Pardi D, Loftus E, et al. Association of age with adverse events from biologic therapy in patients with inflammatory bowel disease. Gastroenterology. 2010;138:A413.

    Article  Google Scholar 

  38. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–5.

    Article  CAS  PubMed  Google Scholar 

  39. Desai A, Zator ZA, de Silva P, et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19:309–15.

    Article  PubMed  Google Scholar 

  40. Widdifield J, Bernatsky S, Paterson JM, et al. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis. Arthritis Care Res. 2013;65:353–61.

    Article  Google Scholar 

  41. Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–33.

    Article  PubMed  Google Scholar 

  42. Toruner M, Loftus Jr EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–36.

    Article  PubMed  Google Scholar 

  43. Boots AM, Maier AB, Stinissen P, et al. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:604–13.

    Article  CAS  PubMed  Google Scholar 

  44. Adult Inflammatory Bowel Disease Physician Performance Measures Set. American Gastroenterological Association. 2011:1–52. Practicing gastroenterologists need to be aware that implementation of steroid-sparing strategies and administering vaccinations may not only decrease infection risk but are incoporated into the quality performance measures by not only the AGA but the Centers for Medicare and Medicaid Services.

  45. Centers for Medicare and Medicaid Services (CMS). Phsyician Quality Reporting System. Available at: http://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/PQRS/index.html; Accessed May 30, 2014.

  46. Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–40.

    Article  PubMed  Google Scholar 

  47. Wasan SK, Calderwood AH, Long MD, et al. Immunization rates and vaccine beliefs among patients with inflammatory bowel disease: an opportunity for improvement. Inflamm Bowel Dis. 2014;20:246–50.

    Article  PubMed  Google Scholar 

  48. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100. The most recent guidelines for vaccinations of the immunosuppressed patient with chronic disease.

    Article  PubMed  Google Scholar 

  49. Moscandrew M, Mahadevan U, Kane S. General health maintenance in IBD. Inflamm Bowel Dis. 2009;15:1399–409.

    Article  PubMed  Google Scholar 

  50. Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231–8.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Christina Y. Ha has received consultancy fees from AbbVie (advisory board) and honoraria from AbbVie and Takeda (speaker’s bureau).

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Digestive Diseases, Center for Inflammatory Bowel Diseases, David Geffen School of Medicine at UCLA, 200 Medical Plaza, Suite 365C, Los Angeles, CA, 90095, USA

    Christina Y. Ha MD

Authors
  1. Christina Y. Ha MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christina Y. Ha MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ha, C.Y. Risks of Infection among the Older Inflammatory Bowel Disease Patients. Curr Treat Options Gastro 12, 283–291 (2014). https://doi.org/10.1007/s11938-014-0023-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-014-0023-x

Keywords

Search

Navigation